1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Postmenopausal Vaginal Atrophy Global Clinical Trials Review, H2, 2015

Postmenopausal Vaginal Atrophy Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Postmenopausal Vaginal Atrophy Global Clinical Trials Review, H2, 2015" provides an overview of Postmenopausal Vaginal Atrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Postmenopausal Vaginal Atrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Postmenopausal Vaginal Atrophy Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Postmenopausal Vaginal Atrophy to Women's Health Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Postmenopausal Vaginal Atrophy to Women's Health Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials 28
Prominent Drugs 30
Clinical Trial Profile Snapshots 31
Appendix 53
Abbreviations 53
Definitions 53
Research Methodology 54
Secondary Research 54
About GlobalData 55
Contact Us 55
Disclaimer 55
Source 55

List of Tables
Postmenopausal Vaginal Atrophy Therapeutics, Global, Clinical Trials by Region, 2015* 6
Postmenopausal Vaginal Atrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Postmenopausal Vaginal Atrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Postmenopausal Vaginal Atrophy to Women's Health Clinical Trials, G7 Countries (%), 2015* 15
Postmenopausal Vaginal Atrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Postmenopausal Vaginal Atrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Postmenopausal Vaginal Atrophy to Women's Health Clinical Trials, E7 Countries (%), 2015* 18
Postmenopausal Vaginal Atrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Postmenopausal Vaginal Atrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Postmenopausal Vaginal Atrophy Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Postmenopausal Vaginal Atrophy Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Postmenopausal Vaginal Atrophy Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 26
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 29
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 30

List of Figures
Postmenopausal Vaginal Atrophy Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Postmenopausal Vaginal Atrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Postmenopausal Vaginal Atrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 10
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Proportion of Postmenopausal Vaginal Atrophy to Women's Health Clinical Trials, G7 Countries (%), 2015* 15
Postmenopausal Vaginal Atrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Postmenopausal Vaginal Atrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Postmenopausal Vaginal Atrophy to Women's Health Clinical Trials, E7 Countries (%), 2015* 18
Postmenopausal Vaginal Atrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Postmenopausal Vaginal Atrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Postmenopausal Vaginal Atrophy Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Postmenopausal Vaginal Atrophy Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Postmenopausal Vaginal Atrophy Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 26
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 30
GlobalData Methodology 54

Companies mentioned
Novo A/S
Shionogi and Co., Ltd.
Quatrx Pharmaceutical Company
Hormos Medical
Pfizer Inc.
Italfarmaco S.p.A.
Duramed Research Inc.
Allergan Plc
Abbott Laboratories
A+ Science AB

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.